Improving diversity in clinical trials for acute leukemia treatments
Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
['FUNDING_CAREER'] · DANA-FARBER CANCER INST · NIH-10874675
This study is looking at why fewer Black and Hispanic adults with acute leukemia join clinical trials and aims to find ways to make it easier for everyone to participate, so that all patients can access the best treatments available.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10874675 on ClinicalTrials.gov |
What this research studies
This research aims to address the significant disparities in clinical trial enrollment among different racial and ethnic groups, particularly focusing on Black and Hispanic adults with acute leukemia. By analyzing existing trial designs and patient behaviors, the study seeks to identify barriers that prevent diverse participation. It will implement a multilevel intervention strategy that includes reviewing trial protocols and integrating data from cancer registries and electronic health records to enhance enrollment diversity. The ultimate goal is to ensure equitable access to innovative therapies and high-quality care for all patients affected by acute leukemia.
Who could benefit from this research
Good fit: Ideal candidates for this research are Black and Hispanic adults diagnosed with acute myeloid leukemia or acute lymphoblastic leukemia.
Not a fit: Patients who do not have acute leukemia or belong to racial and ethnic groups that are already well-represented in clinical trials may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more equitable access to clinical trials and improved treatment outcomes for diverse patient populations with acute leukemia.
How similar studies have performed: Previous research has shown that targeted interventions can successfully improve diversity in clinical trial enrollment, making this approach promising yet innovative.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HANTEL, ANDREW — DANA-FARBER CANCER INST
- Study coordinator: HANTEL, ANDREW
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.